January 30, 2018 / 1:42 PM / 9 months ago

BRIEF-Vaxil Completes Oversubscribed Financing To Advance Cancer Immunotherapy Research

Jan 30 (Reuters) - Vaxil Bio Ltd:

* VAXIL COMPLETES OVERSUBSCRIBED FINANCING TO ADVANCE ITS CANCER IMMUNOTHERAPY RESEARCH AND DEVELOPMENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below